Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke

Details

Veröffentlichungs-Nr.

EP4741007

Anmeldetag

31. Januar 2022

Veröffentlichung

13. Mai 2026

Rechtsraum

EP

IPC

A61K38/17, A61P9/10, G01N33/72A61P9/10(UNIV ZUERICH et al.)(CSL BEHRING AG et al.)

Abstract

The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and/or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.

Anmelder

Firmen

CSL Behring AG
Universität Zürich

Land

🇨🇭 Schweiz